Researchers from Assembly Biosciences Inc. presented the discovery and preclinical characterization of novel small-molecule hepatitis B (HBV) and D virus (HDV) entry inhibitors.
Immune checkpoint inhibitor (ICI) treatment reduced levels of estrogen and important heart-protective proteins, researchers reported in the Nov. 2, 2022, online edition of Science Translational Medicine. Hormone therapies could target this endocrine-cardiac-immune pathway and mitigate myocarditis risk without affecting treatment responses.
X-chromosome inactivation (XCI) is not unique to female cells and may confer some survival advantage to male cancer cells, according to scientists at the Dana-Farber Cancer Institute at Harvard. The noncoding RNA XIST (acronym for X-inactive specific transcript), which in female mammals (of genotype XX) inactivates one of the X chromosomes, preventing the overexpression of the genes of the repeated chromosome from early stages of embryonic development, also acts somatically in some male cancers, compensating for the loss of the entire chromosome.
“We found that a small percentage of male cancers are expressing XIST, which normally is expressed in female cancers. And the percentage of male cancers that express XIST is variable depending on the cancer type,” Srinivas Viswanathan, researcher in the Department of Medical Oncology at the Dana-Farber Cancer Institute at Harvard and assistant professor of Medicine at Harvard Medical School, told BioWorld.
Researchers from Washington University presented data from a study that aimed to identify myeloid-derived suppressor cell (MDSC) markers in patients with multiple sclerosis (MS).
Bayer AG has described phosphorus derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG has divulged imidazo[4,5-d]pyridazinonyl derivatives acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of cough, fibrosis, respiratory tract inflammation and idiopathic pulmonary fibrosis.
Qingdao Ruiji Medical Technology Co. Ltd. has identified benzofuran derivatives acting as farnesoid X receptor (FXR) agonists reported to be useful for the treatment of cancer, inflammation, metabolic, cardiovascular, liver, inflammatory bowel and renal diseases.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
RSS
